Robert Lamey
Internal Medicine · Huntingdon, PANPI 1811971989
Payments from drug & device makers
Across 264 payments — averaging $15.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$671
- AbbVie$579
- Novo Nordisk$536
- GSK$418
- Exact Sciences$154
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$146
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,098100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$4,113 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 134 | $111,689 |
| JardianceEmpagliflozin | 66 | $74,311 |
| TrulicityDulaglutide | 62 | $61,362 |
| OzempicSemaglutide | 55 | $56,109 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 58 | $39,795 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 61 | $29,807 |
| Breo ElliptaFluticasone/Vilanterol | 38 | $14,432 |
| XareltoRivaroxaban | 18 | $12,970 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $7,692 |
| Losartan Potassium | 229 | $3,494 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $3,044 |
| Rosuvastatin Calcium | 127 | $2,691 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 72 | $2,394 |
| Atorvastatin Calcium | 157 | $2,259 |
| Omeprazole | 181 | $2,048 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $115 | $111,689134 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $418 | $84,034157 claims |
| Boehringer IngelheimJardiance | $127 | $74,31166 claims |
| Lilly USA, LLCTrulicity | $671 | $61,36262 claims |
| Novo NordiskOzempic | $536 | $56,10955 claims |
| Johnson & JohnsonXarelto | $94 | $12,97018 claims |
| AstraZenecaBreztri Aerosphere | $76 | $7,69214 claims |
| AbbVieSynthroid | $579 | $94028 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Huntingdon
- Jonathan EpsteinPhiladelphia$13.1M
- Siddharth ShethPittsburgh$11M
- Nathan PatelTannersville$9.5M
- Pitamber DevgonPhiladelphia$7.5M
- Christopher StillDanville$7.1M
- Liza VillaruzPittsburgh$6.6M
- Paul HartleyUniontown$4.9M
- Victor KoladeSayre$4.7M
- Michael OliverBeaver$4.7M
- Raman PurighallaPittsburgh$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.